www.onkologiecs.cz 115 / Onkologie. 2024;18(2):109-115 / ONKOLOGIE HLAVNÍ TÉMA Novinky v terapii difúzního velkobuněčného B-lymfomu LITERATURA 1. Krejčí D, Pehalová L, Talábová A, et al. Současné epidemiologické trendy novotvarů v České republice. ÚZIS Novotvary. 2018(227):345. 2. Vodicka P, Masar M, Klanova M, et al. DLBCL Patients’ Journey: From Symptoms to Diagnosis. Blood. 2023;142(Supplement 1):3140-3140. 3. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511. 4. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690. 5. Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396-1407. 6. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460-468. 7. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351-363. 8. Jardin F, Raghavan V, Tracy S, et al. Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study. Blood. 2023;142(Supplement 1):169-169. 9. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56. 10. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852. 11. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31-42. 12. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640-654. 13. Bishop MR, Dickinson M, Purtill D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022;386(7):629-639. 14. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294-2308. 15. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021;39(18):1959-1970. 16. Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27(9):1902-1909. 17. Chamuleau MED, Burggraaff CN, Nijland M, et al. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. Haematologica. 2020;105(12):2805-2812. 18. Westin J, Nastoupil LJ, Fayad L, et al. Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2019;37(15_suppl):7508-7508. 19. Salles G, Duell J, Gonzalez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978-988. 20. Belada D, Kopeckova K, Bergua JM, et al. First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL. Journal of Clinical Oncology. 2021;39(15_suppl):7540-7540. 21. Vitolo U, Nowakowski GS, Burke JM, et al. frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high- -intermediate and high-risk diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2022;40(16_suppl):TPS7590-TPS7590. 22. Patel K, Orlowski RZ, Doucette K, et al. TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma. Journal of Clinical Oncology. 2022;40(16_ suppl):TPS8071-TPS8071. 23. Patel K, Zonder JA, Sano D, et al. CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First- -in-Human Dose Escalation Study. Blood. 2021;138(Supplement 1):3560-3560. 24. Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/ II Randomized Study and Preliminary Results of a Single-Arm Extension. Blood. 2020;136(Supplement 1):17-19. 25. Vodicka P, Benesova K, Janikova A, et al. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. Eur J Haematol. 2022. 26. Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology. 2021;22(6):790-800. 27. Vodicka P, Klener P, Trneny M. Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options. Onco Targets Ther. 2022;15:1481-1501. 28. Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737-2746. … nenechte si ujít aktuální informace o možnostech medicínského vzdělávání FACEBOOK https://www.facebook.com/ SolenMedicalEducation/ @SolenMedicalEducation LINKEDIN https://www.linkedin.com/ company/solen-medical-education/ #solenmedicaleducation X https://twitter.com/ MedicalSolen @MedicalSolen ODEMČENÉ AKTUÁLNÍ ČLÁNKY PŘEHLED O VZDĚLÁVACÍCH AKCÍCH UPOZORNĚNÍ NA ZVÝHODNĚNÉ CENY SOUTĚŽE O VSTUPENKY NA KONGRESY INFORMACE O ON LINE KURZECH NOVINKY V E SHOPU … a mnoho dalšího
RkJQdWJsaXNoZXIy NDA4Mjc=